Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma

Abstract Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a high mortality rate, while Merkel cell polyomavirus (MCV) has been pointed as the causative agent of MCC. A better prognosis of MCC associated with a high level of antibodies against the capsid protein VP1 suggests that...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dan Xu, Sheng Jiang, Yue He, Xiang Jin, Gan Zhao, Bin Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3588ab04983146199e8e9fd7efbb1b2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3588ab04983146199e8e9fd7efbb1b2b
record_format	dspace
spelling	oai:doaj.org-article:3588ab04983146199e8e9fd7efbb1b2b2021-12-02T18:36:09ZDevelopment of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma10.1038/s41541-021-00382-92059-0105https://doaj.org/article/3588ab04983146199e8e9fd7efbb1b2b2021-10-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00382-9https://doaj.org/toc/2059-0105Abstract Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a high mortality rate, while Merkel cell polyomavirus (MCV) has been pointed as the causative agent of MCC. A better prognosis of MCC associated with a high level of antibodies against the capsid protein VP1 suggests that anti-VP1 immune response might be essential against MCC growth. In the current study, we developed a VP1-target vaccine formulated with CRA. Using a tumorigenic CMS5-VP1 tumor model, the vaccine-induced a potent antitumor efficacy in a dose-dependent manner was evidently demonstrated and mainly mediated by both VP1-specific CD4+ and CD8+ T-cell responses against the growth of CMS5-VP1 tumors in vaccinated BALB/c mice since the depletion of CD4+ and CD8+ T cells reverse the antitumor effects. Thus, immunotherapy with this vaccine represents a novel approach for the clinical treatment of aggressive MCV-related MCC in humans.Dan XuSheng JiangYue HeXiang JinGan ZhaoBin WangNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dan Xu Sheng Jiang Yue He Xiang Jin Gan Zhao Bin Wang Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
description	Abstract Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a high mortality rate, while Merkel cell polyomavirus (MCV) has been pointed as the causative agent of MCC. A better prognosis of MCC associated with a high level of antibodies against the capsid protein VP1 suggests that anti-VP1 immune response might be essential against MCC growth. In the current study, we developed a VP1-target vaccine formulated with CRA. Using a tumorigenic CMS5-VP1 tumor model, the vaccine-induced a potent antitumor efficacy in a dose-dependent manner was evidently demonstrated and mainly mediated by both VP1-specific CD4+ and CD8+ T-cell responses against the growth of CMS5-VP1 tumors in vaccinated BALB/c mice since the depletion of CD4+ and CD8+ T cells reverse the antitumor effects. Thus, immunotherapy with this vaccine represents a novel approach for the clinical treatment of aggressive MCV-related MCC in humans.
format	article
author	Dan Xu Sheng Jiang Yue He Xiang Jin Gan Zhao Bin Wang
author_facet	Dan Xu Sheng Jiang Yue He Xiang Jin Gan Zhao Bin Wang
author_sort	Dan Xu
title	Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
title_short	Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
title_full	Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
title_fullStr	Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
title_full_unstemmed	Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma
title_sort	development of a therapeutic vaccine targeting merkel cell polyomavirus capsid protein vp1 against merkel cell carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3588ab04983146199e8e9fd7efbb1b2b
work_keys_str_mv	AT danxu developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma AT shengjiang developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma AT yuehe developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma AT xiangjin developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma AT ganzhao developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma AT binwang developmentofatherapeuticvaccinetargetingmerkelcellpolyomaviruscapsidproteinvp1againstmerkelcellcarcinoma
_version_	1718377853044654080

Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma

Ejemplares similares